Thursday, GSK Plc (NYSE:GSK) agreed to confidentially settle another lawsuit in California that had alleged its heartburn drug Zantac (ranitidine), now discontinued, caused cancer.
The case, which was set to begin trial on April 2, will be dismissed.
GSK does not admit to any liability in this settlement with Boyd/Steenvoord.
Earlier this month, GSK reached a confidential settlement with David Browne, resolving the case he filed in California state court.
The case was set to go to trial on February 20 and, instead, will now be dismissed, the company said in a statement.
In October, GSK reached a confidential ...